CR2 and stroke disorder: For this study, we utilize CR2-fH, an inhibitor shown to specifically inhibit the alternative pathway [15], and CR2-Crry, an inhibitor of all complement pathways that has been shown to provide acute protection after stroke, but that has not been investigated with regard to subacute outcome [13, 16].